Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BEAM vs GLUE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BEAM Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

BEAM Overall Winner 6-Pillar Tally: BEAM 3 – 2 GLUE (1 Tie) Matrix Metrics: BEAM 5 – 5 GLUE

As of Nov 20, 2026, Beam Therapeutics Inc. (BEAM) is the stronger overall head-to-head candidate over Monte Rosa Therapeutics, Inc. (GLUE) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). BEAM carries a Unified Composite Score of 60.3/100 (BUY) at $20.90 (N/M Forward P/E, -267.7% operating margin), whereas GLUE carries 40.6/100 (SELL) at $8.64 (10.0x Forward P/E, -214.5% operating margin).

  • Growth vs. Quality Trade-Off: BEAM earns the overall head-to-head edge with a stronger Unified Composite Score (60.3/100 BUY vs. GLUE 40.6/100 SELL) and 2.09β · 86% Vol risk profile, whereas GLUE leads top-line expansion (+325.8% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BEAM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.0); meanwhile GLUE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BEAM vs GLUE
BEAM NASDAQ Head-to-Head Winner
Beam Therapeutics Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$20.90
-0.19% 1D
Market Cap $2.2B
TTM Revenue $147M
Forward P/E N/M
Beta / 30D Vol 2.09β · 86% Vol
Unified Composite Score
60.3 / 100 BUY
Tech 70.0 Fund 66.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.3%), weak momentum, RSI 36
RSI-14: 36.0 · SMA20: $24.75 · SMA50: $24.63
GLUE NASDAQ
Monte Rosa Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$8.64
-3.03% 1D
Market Cap $761.4M
TTM Revenue $70M
Forward P/E 10.0x
Beta / 30D Vol 0.87β · 45% Vol
Unified Composite Score
40.6 / 100 SELL
Tech 25.0 Fund 46.0 Flow 64.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.0%), weak momentum, RSI 27
RSI-14: 27.2 · SMA20: $10.06 · SMA50: $10.78

6-Pillar Scorecard Institutional Category Breakdown (BEAM 3 – 2 GLUE)

Columns: Metric · BEAM · GLUE
1. Valuation Multiples GLUE
Forward P/E N/M 10.0x
Trailing P/E N/M 10.0x
PEG Ratio N/M N/M
EV / Revenue 15.3x 10.7x
2. Growth & Scale BEAM
Revenue Growth (YoY) -96.8% +325.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $147M $70M
Market Cap $2.2B $761.4M
3. Profitability & Quality BEAM
Gross Margin N/A N/A
Operating Margin -267.7% -214.5%
Net Profit Margin -73.9% -186.2%
Return on Equity (ROE) -11.3% -35.3%
4. Balance Sheet & Cash Flow GLUE
Cash Generation (TTM) -$398M -$174M
Cash Flow Margin N/A N/A
Net Cash / Leverage $31M Net Debt (0.26x D/E) $8.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BEAM
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 87.4% (34th %ile) 105.8% (17th %ile)
Put/Call OI Skew 2.31x (Put-Skewed) 1.60x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BEAM (5) vs GLUE (5)
Institutional Metric BEAM GLUE Criterion Row Edge
Market Capitalization
Scale
$2.2B $761.4M Larger Scale BEAM
Trailing P/E Ratio
Valuation
N/M 10.0x Lower Multiple GLUE
Forward P/E Ratio
Valuation
N/M 10.0x Lower Multiple GLUE
Revenue Growth (YoY)
Growth
-96.8% +325.8% Higher Growth GLUE
Operating Margin (TTM)
Profitability
-267.7% -214.5% Higher Margin GLUE
Net Profit Margin
Profitability
-73.9% -186.2% Higher Margin BEAM
Return on Equity (ROE)
Capital Efficiency
-11.3% -35.3% Higher ROE BEAM
52-Week Range Position
Momentum
4% ($20–$38) 1% ($8–$26) Stronger Trend BEAM
Beta / 30D Volatility
Risk Regime
2.09β · 86% Vol 0.87β · 45% Vol Lower Realized Risk GLUE
Unified Institutional Score
Composite Signal
60.3 / 100 (BUY) 40.6 / 100 (SELL) Higher Composite BEAM
Trailing 12M Revenue (USD)
Operating Scale
$147M $70M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 15.3x EV/Rev N/M PEG · 10.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$398M ($31M Net Debt (0.26x D/E)) -$174M ($8.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BEAM +7.33 pp
BEAM: -14.9% · GLUE: -22.23%
3M Horizon BEAM +11.05 pp
BEAM: -26.23% · GLUE: -37.28%
6M Horizon BEAM +27.04 pp
BEAM: -27.03% · GLUE: -54.07%
1Y Horizon BEAM +38.52 pp
BEAM: -0.38% · GLUE: -38.9%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BEAM Revenue GLUE Revenue BEAM Op. Margin GLUE Op. Margin Margin Leader
FY2019 $0M N/A -417522.2% N/A BEAM
FY2020 $0M N/A -553166.7% N/A BEAM
FY2021 $50M N/A -757.0% N/A BEAM
FY2022 $60M N/A -555.6% N/A BEAM
FY2023 $380M N/A -46.7% N/A BEAM
FY2024 $60M $80M -654.3% -107.3% GLUE
FY2025 $140M $120M -274.6% -43.8% GLUE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BEAM BREAKDOWN
107d in phase · OBV DISTRIBUTION
Current IV 87.4%
IV Percentile 34th %ile
Put/Call OI Skew 2.31x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact BEAM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GLUE BREAKDOWN
89d in phase · OBV DISTRIBUTION
Current IV 105.8%
IV Percentile 17th %ile
Put/Call OI Skew 1.60x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact GLUE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $20.94 · IV 74.7%

BEAM Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($2,094)

Compare $2,094 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 74.7% ATM IV.

PUT-WALL MONTHLY INCOME Liq C

Dec 18 $20 / $18 Bull Put Spread

Sell 2x $20P · Buy 2x $18P · 28d

Net Entry $102 Credit
Max Credit / Yield +$102 (+34.2% RoM)
Max Risk / Buffer -6.9% Cushion ($298 Mgn)
5d Edge & Liquidity 63% PoP · Liq C
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $23 / $20 Bear Put Spread

Buy 1x $23P · Sell 1x $20P · 28d

Net Entry $179 Debit
T+5d @ -5% Drop +$28 (+16%)
Max Risk / Buffer $179 Capped
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BEAM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and -267.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GLUE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $761.4M market capitalization and -214.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BEAM vs GLUE Key Questions & Quantitative Answers

As of Nov 20, 2026, Beam Therapeutics Inc. (BEAM) is the stronger overall head-to-head candidate over Monte Rosa Therapeutics, Inc. (GLUE) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). BEAM carries a Unified Composite Score of 60.3/100 (BUY) at $20.90 (N/M Forward P/E, -267.7% operating margin), whereas GLUE carries 40.6/100 (SELL) at $8.64 (10.0x Forward P/E, -214.5% operating margin). Growth vs. Quality Trade-Off: BEAM earns the overall head-to-head edge with a stronger Unified Composite Score (60.3/100 BUY vs. GLUE 40.6/100 SELL) and 2.09β · 86% Vol risk profile, whereas GLUE leads top-line expansion (+325.8% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BEAM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.0); meanwhile GLUE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BEAM leads the Growth & Scale pillar: BEAM posts -96.8% YoY revenue growth and +0.0% YoY earnings growth on $147M TTM revenue (N/A gross margin, -267.7% operating margin), compared with GLUE at +325.8% YoY revenue growth and +0.0% YoY earnings growth on $70M TTM revenue (N/A gross margin, -214.5% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), BEAM cumulative revenue shifted +180.0% while GLUE shifted +50.0%. In operating R&D and SG&A reinvestment, BEAM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GLUE.

GLUE screens cheaper on headline valuation multiples. BEAM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 15.3x EV/Revenue (unreported FCF margin), whereas GLUE trades at 10.0x Forward P/E, 10.0x Trailing P/E, N/M PEG, and 10.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BEAM (-11.3% ROE) versus GLUE (-35.3% ROE) capital efficiency.

In options market volatility and institutional positioning, BEAM carries 87.4% implied volatility (34th %ile, Balanced (25th–60th %ile)), a 2.31x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.09β · 86% Vol realized risk). By comparison, GLUE carries 105.8% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.60x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.87β · 45% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.